natgillin/translations-raw huggingface dataset:
In one study, when a single dose of ibuprofen 400 mg was taken within 8 hours before or within 30 minutes after immediate release aspirin dosing (81 mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. 
V eni študiji, v kateri je bil en enkraten odmerek 400 mg ibuprofena uporabljen v 8 urah pred ali v 30 minutah po zaužitju aspirina s takojšnjim sproščanjem (81 mg), se je zmanjšal učinek acetilsalicilne kisline na nastajanje tromboksana ali agregacijo trombocitov.
Other interactions with clopidogrel and ASA 
Druge interakcije s klopidogrelom in z ASA
Hearing loss* or tinnitus* 
Poslabšanje sluha* ali tinitus*
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. 
Podatki epidemioloških študij kažejo večje tveganje za spontani splav, malformacije srca in gastroshize po uporabi zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel. 
Če je potrebna takojšnja korekcija podaljšanega časa krvavitve, lahko učinke klopidogrela odpravi transfuzija trombocitov.
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Germany 
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Nemčija
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy. 
V študiji CURE je 823 (6,6 %) bolnikov sočasno prejemalo tudi antagoniste receptorjev glikoproteinov IIb/IIIa.
Due to the presence of both components of the medicinal product, Clopidogrel/Acetylsalicylic acid Teva is contraindicated in case of: 
Zaradi vsebnosti obeh učinkovin v zdravilu, je zdravilo Klopidogrel/acetilsalicilna kislina Teva kontraindicirano v primeru:
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red 
če imate bolečine v želodcu ali trebuhu ali krvavitev v želodec ali črevo (rdeče blato ali
Some other medicines may influence the use of Clopidogrel/Acetylsalicylic acid Teva or vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Klopidogrel/acetilsalicilna kislina Teva in obratno.
If the use of the combination of clopidogrel/acetylsalicylic acid is discontinued, patients may benefit with continuation of one antiplatelet medicinal product. 
V primeru prenehanja uporabe kombinacije klopidogrela/acetilsalicilne kisline lahko bolniku koristi nadaljevanje uporabe enega antiagregacijskega zdravila.
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. 
Pri manjših urezninah ali poškodbah, npr. če se urežete pri britju, navadno ni razloga za skrb.
In patients with recent transient ischaemic attack or stroke who are at high risk of recurrent ischaemic events, the combination of ASA and clopidogrel has been shown to increase major bleeding. 
Pri bolnikih z nedavnimi tranzitornimi ishemičnimi atakami ali možgansko kapjo, pri katerih obstaja nevarnost ponavljajočih se ishemij, je dokazano, da kombinacija ASA in klopidogrela poveča hudo krvavitev.
At high ASA doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher. 
Pri velikih odmerkih ASA poteka odstranjevanje salicilne kisline s kinetiko ničelnega reda (tj. delež odstranjevanja je konstanten glede na koncentracijo v plazmi), navidezni razpolovni čas pa je 6 ur ali več.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja v višini 22 % (IZ: 8,6; 33,4), 32 % (IZ: 12,8; 46,4), 4 % (IZ: -26,9; 26,7), 6 % (IZ: -33,5; 34,3) in 14 % (IZ: -31,6; 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intervali študije.
Until the 24th amenorrhea week (5th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary. 
Do 24. tedna amenoreje (5. mesec nosečnosti) se acetilsalicilne kisline ne sme uporabljati, če ni nujno potrebno.
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren-Weiler Germany 
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren-Weiler Nemčija
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge. 
Pri bolnikih, pri katerih ni bila opravljena angiografija, sta bila primarna opazovana dogodka smrt ali ponovni miokardni infarkt do 8. dneva oziroma do odpusta iz bolnice.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. 
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze tega zdravila ne smejo jemati.
If you stop taking Clopidogrel/Acetylsalicylic acid Teva Do not stop the treatment unless your doctor tells you so. 
Če ste prenehali jemati zdravilo Klopidogrel/acetilsalicilna kislina Teva Ne prekinite zdravljenja, razen če vam tega ne odredi zdravnik.
It is unknown whether clopidogrel is excreted in human breast milk. 
Ni znano, ali se klopidogrel izloča v materino mleko pri človeku.
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss. 
V klinični študiji pri zdravih prostovoljcih je sočasna uporaba klopidogrela in naproksena povečala okultno izgubo krvi iz prebavil.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition. 
Ker aktivni presnovek nastane z delovanjem encimov CYP450, med katerimi so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, zavrtje trombocitov pri vseh bolnikih ne bo zadostno.
Clopidogrel: During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes. 
Klopidogrel: V predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V študiji CAPRIE je bila pri bolnikih, zdravljenih ali s klopidogrelom ali z ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
EXP After first opening bottle use within 30 days. 
EXP Porabiti v 30 dneh po prvem odprtju plastenke.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen. 
Poleg tega je bilo IPA 32 % (24 ur) in 61 % (5. dan), kar je več kot pri slabih metabolizatorjih, ki so prejemali shemo 300 mg/75 mg in podobno kot pri drugih metabolizatorskih skupinah s CYP2C19, ki so prejemale shemo 300 mg/75 mg.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours. 
Ta koristni učinek je bil prisoten pri vseh starostih, obeh spolih, ob uporabi ali o neuporabi fibrinolitikov, opažen pa je bil že po 24 urah.
5.1 Pharmacodynamic properties Pharmacotherapeutic group: platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30. 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina; oznaka ATC: B01AC30
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel. 
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, kot so antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
Patients with pre-existing mastocytosis, in whom the use of acetylsalicylic acid may induce severe hypersensitivity reactions (including circulatory shock with flushing, hypotension, tachycardia and vomiting). 
Bolniki s predhodno prisotno mastocitozo, pri katerih lahko uporaba acetilsalicilne kisline povzroči resne preobčutljivostne reakcije (vključno s cirkulacijskim šokom z zardevanjem, hipotenzijo, tahikardijo in bruhanjem).
Salicylic acid in the combination of clopidogrel/acetylsalicylic acid has a plasma half-life of approximately 2 hours. 
Salicilna kislina iz kombinacije klopidogrela/acetilsalicilne kisline ima plazemski razpolovni čas približno 2 uri.
• swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
• otekanje ust ali bolezni kože, kot so izpuščaji, srbenje in mehurji na koži.
In any case, you should take it for as long as your doctor continues to prescribe it. 
Vsekakor morate zdravilo jemati toliko časa, kot vam naroči zdravnik.
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel. 
Podatki študije CAPRIE kažejo, da je sočasna uporaba fenitoina in tolbutamida, ki se presnavljata s CYP2C9, s klopidogrelom varna.
Consequently, the concomitant use of NSAIDs including Cox-2 inhibitors is not recommended (see section 4.4). 
Posledično, sočasna uporaba NSAID, vključno z zaviralci Cox-2, ni priporočljiva (glejte poglavje 4.4).
The safety and efficacy of clopidogrel plus ASA have been evaluated in three double-blind studies involving over 61,900 patients: the CURE, CLARITY and COMMIT studies, comparing clopidogrel plus ASA to ASA alone, both treatments given in combination with other standard therapy. 
Varnost in učinkovitost klopidogrela in ASA sta bili ocenjeni v treh dvojno slepih raziskavah, v katere je bilo vključenih več kot 61.900 bolnikov, in sicer študije CURE, CLARITY in COMMIT, ki so primerjale kombinacijo klopidogrela in ASA s samo ASA; obe terapiji so bolniki prejemali v kombinaciji z drugo standardno terapijo.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni opazovani dogodki so bili navzočnost z infarktom povezane zamašene arterije na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
• In patients with a history of asthma or allergic disorders since they are at increased risk of hypersensitivity reactions 
• Pri bolnikih z astmo ali alergijskimi boleznimi v anamnezi, ker je prisotno večje tveganje za
A total of 99.7% of patients received fibrinolytics (fibrin-specific: 68.7%, non-fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Skupno je 99,7 % bolnikov prejemalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % zaviralce adrenergičnih receptorjev beta, 54,7 % zaviralce ACE in 63 % statine.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used. 
Ta koristni učinek je bil prisoten v vseh prehodno opredeljenih podskupinah glede na bolnikovo starost ali spol, mesto infarkta in tip uporabljenega fibrinolitika ali heparina.
Clopidogrel plus ASA significantly reduced the relative risk of death from any cause by 7% (p = 0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p = 0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Klopidogrel in ASA sta pomembno zmanjšala relativno tveganje za smrt zaradi kateregakoli vzroka za 7 % (p=0,029) in relativno tveganje za kombinacijo ponovnega infarkta, kapi ali smrti za 9 % (p=0,002), kar predstavlja absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Teva How to take Clopidogrel/Acetylsalicylic acid Teva 
Kaj je zdravilo Klopidogrel/acetilsalicilna kislina Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel/acetilsalicilna kislina Teva Kako jemati zdravilo Klopidogrel/acetilsalicilna kislina Teva
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent effects on hemostasis. 
Čeprav uporaba klopidogrela 75 mg/dan ni spremenila farmakokinetike S-varfarina ali internacionalnega normaliziranega razmerja (INR) pri bolnikih, ki so se dolgotrajno zdravili z varfarinom, sočasna uporaba klopidogrela in varfarina pa poveča tveganje krvavitev zaradi neodvisnih vplivov na hemostazo.
Patients with a confirmed diagnosis of acquired haemophilia should be managed and treated by specialists, and Clopidogrel/Acetylsalisylic acid should be discontinued. 
Bolnike s potrjeno diagnozo pridobljene hemofilije morajo obravnavati in zdraviti specialisti, zdravljenje s kombinacijo klopidogrela/acetilsalicilne kisline pa je treba prekiniti.
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy. 
Študija CLARITY je vključevala 3.491 bolnikov v 12 urah po nastopu akutnega miokardnega infarkta z elevacijo ST spojnice, ki so bili predvideni za trombolitično terapijo.
Based on the pharmacokinetic and metabolic characteristics of both compounds, clinically significant PK interactions are unlikely 
Glede na farmakokinetične in presnovne značilnosti obeh snovi klinično pomembne farmakokinetične interakcije niso verjetne.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects'). 
• nemudoma obvestite svojega zdravnika, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »Možni neželeni učinki«).
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
• če imate kakšno bolezen, ki trenutno povzroča krvavitev, kot je razjeda na želodcu ali krvavitev v možganih,
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. 
Zavrtje sinteze prostaglandinov ima lahko neželene učinke na nosečnost in/ali razvoj zarodka oz. ploda.
Due to the presence of ASA, methotrexate used at doses higher than 20 mg/week should be used with caution with the combination of clopidogrel/acetylsalicylic acid as it can inhibit renal clearance of methotrexate, which may lead to bone marrow toxicity. 
Zaradi vsebnosti ASA je med sočasno uporabo metotreksata, ki se uporablja v odmerku višjem od 20 mg/teden, s kombinacijo klopidogrela/acetilsalicilne kisline potrebna previdnost, saj lahko zavre ledvični očistek metotreksata, kar lahko povzroči toksične učinke na kostni mozeg.
Animal studies have shown excretion of clopidogrel in breast milk. 
Študije na živalih so pokazale, da se klopidogrel izloča v materino mleko.
In CURE, CLARITY, ACTIVE-A and one of the cohort studies (Trenk), no increased event rate was observed based on metaboliser status. 
V študijah CURE, CLARITY, ACTIVE-A in eni od kohortnih študij (Trenk) niso zaznali večjega deleža dogodkov glede na obseg presnove.
Upper gastrointestinal disorders (oesophagitis, oesophageal ulceration, perforation, erosive gastritis, erosive duodenitis; gastro-duodenal ulcer/perforations)*; lower gastrointestinal disorders (small [jejunum and ileum] and large [colon and rectum] intestinal ulcers, colitis and intestinal perforation)*; upper gastro-intestinal symptoms* such as gastralgia (see section 4.4); these ASA-related GI reactions may or may not be associated with haemorrhage, and may occur at any dose of acetylsalicylic acid and in patients with or without warning symptoms or a previous history of serious GI events*. 
Bolezni zgornjih prebavil (ezophagitis, ulkus požiralnika, perforacija, erozivni gastritis, erozivni duodenitis; razjede/perforacije na želodcu/dvanajstniku*; bolezni spodnjih prebavil (tankega [jejunum in ileum] in debelega črevesa [kolon in rektum], intestinalni ulkusi, kolitis in perforacije prebavil)*, simptomi zgornjih prebavil*, npr. gastralgija (glejte poglavje 4.4); te z ASA povezane gastrointestinalne reakcije, so lahko ali pa tudi ne povezane s krvavitvijo ter se lahko pojavijo pri katerem koli odmerku acetilsalicilne kisline in pri bolnikih z ali brez opozorilnih simptomov ali predhodne anamneze resnih gastrointestinalnih dogodkov*.
Salicylic acid is widely distributed to all tissues and fluids in the body, including the central nervous system, breast milk, and foetal tissues. 
Salicilna kislina se v veliki meri porazdeli po vseh telesnih tkivih in tekočinah, tudi v osrednjem živčevju, materinem mleku in tkivih ploda.
After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. 
Po enkratnem odmerku in večkratnih peroralnih odmerkih 75 mg na dan se klopidogrel hitro absorbira.
Salicylate metabolism is saturable and total body clearance decreases at higher serum concentrations due to the limited ability of the liver to form both salicyluric acid and phenolic glucuronide. 
Presnova salicilatov je saturabilna, celotni telesni očistek pa se pri velikih koncentracijah v serumu zmanjša zaradi omejene zmožnosti jeter za tvorbo salicilurične kisline in fenolnega glukuronida.
Clopidogrel/Acetylsalicylic acid Teva is not intended for use in children or adolescents less than 18 years of age. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva ni namenjeno uporabi pri otrocih in mladostnikih, mlajših od 18 let.
• If you are allergic to other products called non-steroidal anti-inflammatory products usually used to treat painful and/or inflammatory conditions of muscles or joints. 
• če ste alergični na druga zdravila, imenovana nesteroidna protivnetna zdravila, ki se običajno uporabljajo za zdravljenje bolečih in/ali vnetja mišic ali sklepov,
Acute renal impairment (especially in patients with existing renal impairment, heart decompensation, nephritic syndrome, or concomitant treatment with diuretics)*, glomerulonephritis, blood creatinine increased 
Akutna okvara ledvic (zlasti pri bolnikih z obstoječo okvaro ledvic, srčnim popuščanjem, nefritičnim sindromom ali bolnikih, ki so deležni sočasnega zdravljenja z diuretiki)*, glomerulonefritis, zvišanje kreatinina v krvi
• The active substances are clopidogrel and acetylsalicylic acid. 
• Zdravilni učinkovini sta klopidogrel in acetilsalicilna kislina.
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. 
Alela CYP2C19*2 in CYP2C19*3 predstavljata del alelov z zmanjšanim delovanjem pri belcih (85%) in pri Azijcih (99 %), ki so slabi metabolizatorji.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450. 
Klopidogrel se in vitro in in vivo presnovi po dveh glavnih presnovnih poteh: ena poteka z esterazami, kar vodi do hidrolize v njegov neaktiven karboksilnokislinski derivat (85 % presnovkov v obtoku), druga pa z več encimi citokroma P450.
Clopidogrel/Acetylsalicylic acid Teva contains lactose If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine. 
Zdravilo Klopidogrel/acetilsalicilna kislina Teva vsebuje laktozo Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev (npr. laktoze), se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. 
Farmakokinetika digoksina ali teofilina ni bila spremenjena pri sočasni uporabi klopidogrela.
Oral use SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT Keep out of the sight and reach of children. 
peroralna uporaba POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN Zdravilo shranjujte nedosegljivo otrokom!
Therefore, the combination of clopidogrel/acetylsalicylic acid should be used with caution in these patients. 
Zato je pri uporabi kombinacije klopidogrela/acetilsalicilne kisline pri teh bolnikih potrebna previdnost.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. 
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani celotno njihovo preostalo življenjsko dobo (približno 7 do 10 dni), normalno delovanje trombocitov pa se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.
Marketing Authorisation Holder: Teva Pharma B.V. 
Imetnik dovoljenja za promet: Teva Pharma B.V.
• inflammation of small vessels. 
• vnetje malih žil.
Activated charcoal (adsorbent) and sodium sulphate (laxative) are then administered. 
Za tem je treba uporabiti aktivno oglje (adsorbent) in natrijev sulfat (odvajalo).
- renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; 
- motenemu delovanju ledvic, ki lahko napreduje v odpoved ledvic in oligohidramnij,
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers. 
V študiji TRITON-TIMI 38 in 3 kohortnih študijah (Collet, Sibbing, Giusti) je bila v združeni skupini bolnikov, ki so bili ali srednje dobri ali slabi metabolizatorji, prisotna večja stopnja kardiovaskularnih dogodkov (smrt, miokardni infarkt, možganska kap) ali tromboz na žilni opornici kot pri obsežnih metabolizatorjih.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel plus ASA and ASA alone was not significantly affected by the concomitant heparin therapy. 
Heparine so uporabljali pri več kot 90 % bolnikov, sočasna uporaba heparinske terapije pa ni pomembno vplivala na relativni delež krvavitev med klopidogrelom in ASA ter samo ASA.
You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in place of the two separate medicines, clopidogrel and ASA, to help prevent blood clots because you have experienced a severe type of chest pain known as ‘unstable angina' or heart attack (myocardial infarction). 
Zdravnik vam je predpisal zdravilo Klopidogrel/acetilsalicilna kislina Teva namesto dveh posameznih zdravil, klopidogrela in ASA, kot pomoč pri preprečevanju nastanka krvnih strdkov, ker ste imeli hudo obliko bolečine v prsih, znano kot »nestabilna angina pektoris«, ali ker ste imeli srčni infarkt (miokardni infarkt).
Light pink to pink, film-coated capsule shaped tablets. 
Svetlo roza do roza, filmsko obložene tablete v obliki kapsule.
Depending on your condition, your doctor will determine the length of time for which you need to take Clopidogrel/Acetylsalicylic acid Teva. 
Zdravnik bo glede na vaše stanje določil, koliko časa morate jemati zdravilo Klopidogrel/acetilsalicilna kislina Teva.